ABSI logo

Absci (ABSI) Company Overview

Profile

Full Name:

Absci Corporation

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 22, 2021

Indexes:

Not included

Description:

AbSci is a biotechnology company that focuses on using advanced technology to create new drugs. They specialize in protein engineering and synthetic biology to develop therapies for various diseases, aiming to improve the drug discovery process and make treatments more effective and accessible.

Events Calendar

Earnings

Next earnings date:

Mar 21, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 21, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 22, 25 Needham
Buy
Jan 17, 25 HC Wainwright & Co.
Buy
Jan 10, 25 HC Wainwright & Co.
Buy
Jan 8, 25 Keybanc
Overweight
Jan 8, 25 HC Wainwright & Co.
Buy
Dec 13, 24 HC Wainwright & Co.
Buy
Dec 3, 24 Guggenheim
Buy
Nov 13, 24 HC Wainwright & Co.
Buy
Oct 2, 24 Guggenheim
Buy
Aug 15, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
ABSI
globenewswire.comJanuary 22, 2025

VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.

Absci Looks Cheap And Positioned For Growth With AMD's AI Backing
Absci Looks Cheap And Positioned For Growth With AMD's AI Backing
Absci Looks Cheap And Positioned For Growth With AMD's AI Backing
ABSI
seekingalpha.comJanuary 13, 2025

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI's main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI's AI models and wet lab data seem quite promising for discovering further antibodies that could be highly differentiated from other competitors.

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
ABSI
globenewswire.comJanuary 10, 2025

Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics

Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
ABSI
globenewswire.comJanuary 6, 2025

Collaboration leverages Absci's leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications Collaboration leverages Absci's leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications

Absci Corporation (ABSI) Q3 2024 Earnings Call Transcript
Absci Corporation (ABSI) Q3 2024 Earnings Call Transcript
Absci Corporation (ABSI) Q3 2024 Earnings Call Transcript
ABSI
seekingalpha.comNovember 12, 2024

Absci Corporation (NASDAQ:ABSI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Srikripa Devarakonda – Truist Securities Brendan Smith - TD Cowen George Farmer – Scotiabank Vamil Divan - Guggenheim Securities Operator Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call.

Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
ABSI
globenewswire.comNovember 12, 2024

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration

Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
ABSI
globenewswire.comOctober 15, 2024

VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before market open on Tuesday, November 12, 2024.

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
ABSI
seekingalpha.comOctober 3, 2024

Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features like de novo antibody creation, multiparameter lead optimization, and reverse immunology, potentially offering superior potency and dosing flexibility. The global Crohn's Disease treatment market is expected to reach $17.80 billion by 2033.

Absci to Participate in Upcoming Investor Conferences
Absci to Participate in Upcoming Investor Conferences
Absci to Participate in Upcoming Investor Conferences
ABSI
globenewswire.comAugust 21, 2024

VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

Absci Corporation (ABSI) Q2 2024 Earnings Call Transcript
Absci Corporation (ABSI) Q2 2024 Earnings Call Transcript
Absci Corporation (ABSI) Q2 2024 Earnings Call Transcript
ABSI
seekingalpha.comAugust 16, 2024

Absci Corporation (NASDAQ:ABSI ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Steven Mah - TD Cowen Srikripa Devarakonda - Truist George Farmer - Scotiabank Scott Schoenhaus - KeyBanc Operator Good day and thank you for standing by. Welcome to the Absci Second Quarter 2024 Business Update Conference Call.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Absci?
  • Does Absci pay dividends?
  • What sector is Absci in?
  • What industry is Absci in?
  • What country is Absci based in?
  • When did Absci go public?
  • Is Absci in the S&P 500?
  • Is Absci in the NASDAQ 100?
  • Is Absci in the Dow Jones?
  • When was Absci's last earnings report?
  • When does Absci report earnings?
  • Should I buy Absci stock now?

What is the ticker symbol for Absci?

The ticker symbol for Absci is NASDAQ:ABSI

Does Absci pay dividends?

No, Absci does not pay dividends

What sector is Absci in?

Absci is in the Healthcare sector

What industry is Absci in?

Absci is in the Biotechnology industry

What country is Absci based in?

Absci is headquartered in United States

When did Absci go public?

Absci's initial public offering (IPO) was on July 22, 2021

Is Absci in the S&P 500?

No, Absci is not included in the S&P 500 index

Is Absci in the NASDAQ 100?

No, Absci is not included in the NASDAQ 100 index

Is Absci in the Dow Jones?

No, Absci is not included in the Dow Jones index

When was Absci's last earnings report?

Absci's most recent earnings report was on Nov 12, 2024

When does Absci report earnings?

The next expected earnings date for Absci is Mar 21, 2025

Should I buy Absci stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions